SSX9 inhibitors represent a class of chemical compounds that specifically target and inhibit the activity of the SSX9 protein. SSX9, part of the Synovial Sarcoma X breakpoint protein family, is a transcriptional regulator involved in various cellular processes. These inhibitors function by binding to specific active sites or regulatory domains of the SSX9 protein, thereby hindering its ability to interact with other molecular targets or participate in the transcriptional machinery. This inhibition can result in the modulation of gene expression patterns, which can have far-reaching effects on cellular functions such as differentiation, proliferation, and apoptosis. The design and synthesis of SSX9 inhibitors involve a thorough understanding of the protein's structure, including its active sites, binding pockets, and interaction surfaces. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often employed to elucidate these structural details and guide the development of potent and selective inhibitors.
The chemical architecture of SSX9 inhibitors can vary widely, incorporating diverse functional groups and scaffolds to achieve optimal binding affinity and specificity. Common structural features include heterocyclic cores, aromatic rings, and hydrophobic moieties that enhance interactions with the SSX9 protein. Additionally, these inhibitors may be designed to possess favorable physicochemical properties, such as solubility and stability, to facilitate their experimental use. Advanced synthetic techniques, including combinatorial chemistry and high-throughput screening, are often utilized to generate and evaluate large libraries of potential inhibitors. Once promising candidates are identified, further refinement through medicinal chemistry approaches, such as structure-activity relationship (SAR) studies, can optimize their inhibitory efficacy. Overall, the development of SSX9 inhibitors involves a multidisciplinary approach, integrating structural biology, synthetic chemistry, and molecular biology to achieve precise modulation of the SSX9 protein's activity.
더보기
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
또 다른 HDAC 억제제는 클래스 I 및 II HDAC를 억제하고 유전자 발현을 변화시키는 것으로 알려져 있습니다. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
주로 항경련제로 사용되지만 후성유전학적 조절에도 영향을 미치는 HDAC 억제제입니다. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
염색질 구조와 유전자 발현에 영향을 미치는 HDAC 억제제로서 기능하는 고리형 펩타이드. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA에 결합하여 메틸화를 억제하여 침묵된 유전자의 재활성화를 유도하는 DNA 메틸 트랜스퍼라제 억제제. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
효소&프라임의 활성 부위에 결합하여 DNA 메틸화를 방지하는 비뉴클레오사이드 DNA 메틸전달효소 억제제입니다. |